Edition:
United Kingdom

Shanghai Fosun Pharmaceutical Group Co Ltd (2196.HK)

2196.HK on Hong Kong Stock

24.05HKD
17 May 2019
Change (% chg)

-- (--)
Prev Close
HK$24.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,824,942
52-wk High
HK$51.65
52-wk Low
HK$19.76

Latest Key Developments (Source: Significant Developments)

Shanghai Fosun Pharmaceutical Says Unit Gets Certificate Of Drug Registration Approval By NMPA
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::SHANGHAI FOSUN PHARMACEUTICAL GROUP-SHANGHAI HENLIUS BIOPHARMACEUTICAL GETS CERTIFICATE OF DRUG REGISTRATION APPROVAL FOR NEW DRUG ISSUED BY NMPA.  Full Article

Shanghai Fosun Pharma's JV Shanghai Henlius Biotech Submits Hong Kong IPO Application To Exchange
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>2196.HK::SAYS ITS JV SHANGHAI HENLIUS BIOTECH INC HAS SUBMITTED ITS H-SHARES INITIAL PUBIC OFFERING APPLICATION TO HONG KONG STOCK EXCHANGE ON DEC 13.  Full Article

Fosun International Updates On Proposed Spin-Off Of Shanghai Henlius
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Fosun International Ltd <0656.HK>::FOSUN PHARMA AND CO MADE JOINT APPLICATION TO HONG KONG STOCK EXCHANGE FOR APPROVAL OF PROPOSED SPIN-OFF OF SHANGHAI HENLIUS.  Full Article

Revance Announces China Market License Agreement With Fosun Pharma For RT002
Tuesday, 4 Dec 2018 

Dec 4 (Reuters) - Revance Therapeutics Inc ::REVANCE ANNOUNCES CHINA MARKET LICENSE AGREEMENT WITH FOSUN PHARMA FOR RT002.REVANCE THERAPEUTICS INC - UPFRONT PAYMENT OF $30 MILLION, PLUS POTENTIAL MILESTONE PAYMENT AND TIERED ROYALTIES ON FUTURE SALES.REVANCE THERAPEUTICS INC - REVANCE ELIGIBLE TO RECEIVE ADDITIONAL POTENTIAL DEVELOPMENT AND SALES MILESTONE PAYMENTS OF UP TO $230.5 MILLION.REVANCE THERAPEUTICS INC - NO TRANSFER OF INTELLECTUAL PROPERTY..REVANCE THERAPEUTICS INC - REVANCE ELIGIBLE TO RECEIVE TIERED LOW-DOUBLE-DIGIT TO HIGH-TEEN ROYALTY PAYMENTS ON FUTURE NET SALES FROM DEAL.REVANCE THERAPEUTICS INC - FOSUN PHARMA WILL BE RESPONSIBLE FOR CONDUCTING NECESSARY CLINICAL STUDIES, MARKETING AND SALES IN TERRITORY.REVANCE THERAPEUTICS - FOSUN HAS EXCLUSIVE RIGHTS TO DEVELOP, COMMERCIALIZE DAXIBOTULINUMTOXINA FOR INJECTION IN MAINLAND CHINA, HONG KONG AND MACAU.  Full Article

Shanghai Fosun Pharmaceutical Says 9-Month Net Profit Down 13.4 Percent Y/Y
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>2196.HK::SAYS 9-MONTH NET PROFIT DOWN 13.4 PERCENT Y/Y.  Full Article

Diamedica Therapeutics And Ahon Pharma Announce Signing Of License Agreement For Dm199 In China
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - DiaMedica Therapeutics Inc ::DIAMEDICA THERAPEUTICS AND AHON PHARMA, A FOSUN PHARMA PORTFOLIO COMPANY, ANNOUNCES SIGNING OF LICENSE AGREEMENT FOR DM199 IN CHINA FOR ACUTE ISCHEMIC STROKE.DIAMEDICA -AGREEMENT ALLOWS AHON TO HAVE EXCLUSIVE RIGHTS TO DEVELOP & COMMERCIALIZE DM199 IN MAINLAND CHINA, TAIWAN, HONG KONG S.A.R. AND MACAU S.A.R.DIAMEDICA THERAPEUTICS - UNDER TERMS OF AGREEMENT, CO IS ENTITLED TO RECEIVE AN UPFRONT PAYMENT OF $5 MILLION, UPON CLEARANCE TO INITIATE CLINICAL TRIAL IN CHINA.DIAMEDICA -HAS POTENTIAL TO RECEIVE $27.5 MILLION IN DEVELOPMENT, SALES RELATED MILESTONES,HIGH SINGLE & LOW DOUBLE-DIGIT ROYALTIES ON NET SALES OF DM199.  Full Article

Shanghai Fosun Pharmaceutical Group Approves Proposed Overseas Listing Of Shanghai Henlius Biotech, Inc
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::BOARD APPROVED PROPOSED OVERSEAS LISTING OF SHANGHAI HENLIUS BIOTECH, INC ON STOCK EXCHANGE OF HONG KONG LTD.  Full Article

Shanghai Fosun Pharma Group Says Conclusive Opinion Of Chongqing FDA's Unannounced Inspection Yet To Be Finalised
Friday, 31 Aug 2018 

Aug 31 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::SHANGHAI FOSUN PHARMACEUTICAL GROUP CO LTD - CLARIFIES ON RECENT MEDIA REPORTS.SHANGHAI FOSUN PHARMACEUTICAL GROUP CO - ON AUG 23, CHONGQING FDA MADE UNANNOUNCED INSPECTION AT CHONGQING RESEARCH INSTITUTE.SHANGHAI FOSUN PHARMACEUTICAL GROUP CO - CONCLUSIVE OPINION OF CHONGQING FDA'S UNANNOUNCED INSPECTION YET TO BE FINALISED.SHANGHAI FOSUN PHARMACEUTICAL-CHONGQING FDA GOT LETTER ON BREACH OF DRUG ADMINSTARTION LAW BY PHARMA CO OF CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE.  Full Article

Shanghai Fosun Pharma Clarifies Media Reports, Says Unit Checked By Medicine Regulator
Thursday, 30 Aug 2018 

Aug 31 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>2196.HK ::SAYS MEDICINE REGULATOR HAS CHECKED ITS CHONGQING UNIT BUT HAS NOT HAD CONCLUSION YET, RESPONDING TO MEDIA REPORTS THAT ITS UNIT VIOLATED MEDICINE REGULATIONS.SAYS IT WILL MONITOR DEVELOPMENTS CLOSELY AND DISCLOSE RELATED INFORMATION ON TIME.  Full Article

Shanghai Fosun Pharmaceutical Group to pay cash dividend of 0.38 yuan per share on Aug. 3
Friday, 27 Jul 2018 

July 27 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>:Says it will pay a cash dividend of 0.38 yuan per share (before tax) for 2017 to shareholders of record on Aug. 2.The company's shares will be traded ex-right and ex-dividend on Aug. 3 and the dividend will be paid on Aug. 3 .  Full Article